New drug duo aims to keep relapsed germ cell cancer in check

NCT ID NCT06937866

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking two drugs (zanzalintinib and oral etoposide) after high-dose chemotherapy can help keep relapsed germ cell tumors from growing. About 38 adults whose cancer has not been cured by standard treatments will participate. The goal is to see if this combination is safe and can delay cancer progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extragonadal nonseminomatous germ cell tumor germ cell tumor malignant testicular germ cell tumor Neoplasms, Germ Cell and Embryonal nongerminomatous germ cell tumor ovarian germ cell tumor seminoma testis refractory cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact